Core Viewpoint - Aclaris Therapeutics reported a quarterly loss of $0.12 per share, outperforming the Zacks Consensus Estimate of a loss of $0.17, and showing improvement from a loss of $0.24 per share a year ago, indicating a positive earnings surprise of 29.41% [1] Financial Performance - The company posted revenues of $1.46 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 65.15%, compared to revenues of $2.4 million in the same quarter last year [2] - Over the last four quarters, Aclaris has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Aclaris shares have declined approximately 49.6% since the beginning of the year, contrasting with the S&P 500's decline of 4.3% [3] - The current Zacks Rank for Aclaris is 3 (Hold), indicating that the shares are expected to perform in line with the market in the near future [6] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.19 on revenues of $4.28 million, and for the current fiscal year, it is -$0.71 on revenues of $17.33 million [7] - The trend of estimate revisions for Aclaris is mixed, which could change following the recent earnings report [6] Industry Context - The Medical - Drugs industry, to which Aclaris belongs, is currently ranked in the top 26% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Plus Therapeutics, is expected to report a quarterly loss of $0.17 per share, with a year-over-year change of +77.3% [9]

分组1 - Theravance Biopharma reported a quarterly loss of $0.05 per share, consistent with the Zacks Consensus Estimate, compared to earnings of $0.03 per share a year ago [1] - The company posted revenues of $18.75 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 3.50% and up from $17.57 million year-over-year [2] - Over the last four quarters, Theravance Biopharma has surpassed consensus EPS estimates two times and revenue estimates two times [2][1] 分组2 - The stock has underperformed, losing about 4.7% since the beginning of the year, while the S&P 500 gained 1.3% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.12 on revenues of $17.65 million, and for the current fiscal year, it is $0.84 on revenues of $111.23 million [7] - The Zacks Industry Rank for Medical - Drugs is in the top 50% of over 250 Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Amendment No. 1 to FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) Table of Contents As filed with the Securities and Exchange Commission on June 24, 2024 Registration No. 333-280061 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 (I.R.S. Employer ...

As filed with the Securities and Exchange Commission on June 7, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code Number) Delaware 2834 33-0827593 (I.R.S. Employer Identification Number) 4200 Marathon Blvd., ...

Table of Contents As filed with the Securities and Exchange Commission on March 8, 2024 Registration No. 333-275712 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 AMENDMENT NO. 1 TO Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer ...

Table of Contents As filed with the Securities and Exchange Commission November 22, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 (Exact name of Registrant as specified in its charter) Delaware 2834 33-0827593 (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial (I.R.S. Employer Identification Number) 4200 Marathon Blvd., Suite 200 Austin, TX 78756 (737)-255-7194 (Address, including zip code, and telephone number, in ...

Table of Contents As filed with the Securities and Exchange Commission November 14, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 PLUS THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 33-0827593 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) ...

Table of Contents As filed with the Securities and Exchange Commission August 9, 2023 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 Andrew Sims Chief Financial Officer Plus Therapeutics, Inc. 4200 Marathon Blvd., Suite 200 Austin, TX 78756 (737)-255-7194 (Name, address, including zip code, and telephone number, including area code, of agent for service) PLUS THERAPEUTICS, INC. (Exact name of Regi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (previously known as Cytori Therapeutics, Inc.) (Exact name of Registrant as Specified in Its Charter) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-34375 PLUS THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) DELAWARE 33-0827593 (State or other jur ...